1: Curr Med Chem. 2005;12(12):1361-94. 

Current knowledge on the antagonists and inverse agonists of cannabinoid
receptors.

Muccioli GG, Lambert DM.

Unite de Chimie pharmaceutique et de Radiopharmacie, Universite catholique de
Louvain, Avenue E. Mounier, 73, UCL-CMFA7340, B-1200 Bruxelles, Belgium.
lambert@cmfa.ucl.ac.be.

Ten years elapsed since the discovery by Sanofi of SR141716A the first selective
CB(1) cannabinoid receptor antagonist. Shortly after, Sanofi also reported the
synthesis of the first selective CB(2) cannabinoid receptor antagonist,
SR144528. Since these two milestones in the cannabinoid field, many other
compounds, more or less related to the Sanofi compounds, or based on a
completely different scaffold appeared. Several of these compounds are currently
involved in clinical trials for diseases such as obesity, nicotine and alcohol
addictions, or allergies. Further, the cannabinoid receptors knock-out mice
production strengthened the hypothesis of the existence of several other
"cannabinoid" receptors for which the first antagonists begin to appear. The
large amount of patents taken by many different pharmaceutical companies prove,
if necessary, the great therapeutic potential expected for the cannabinoid
receptors antagonists.

PMID: 15974990 [PubMed - in process]